Immune checkpoint inhibitor-induced vitiligo in advanced melanoma could be related to increased levels of CCL19.
Immune checkpoint inhibitors (ICIs) are in wide use for the treatment of various cancers. Although anti-PD-1 antibody (Ab)-based combined therapy might be effective for the treatment of advanced melanoma, the associated risk of immune-related adverse events (irAEs) is an important consideration 1, 2 . In contrast to these severe AEs, vitiligo is reported to correlate with improved prognosis among advanced melanoma patients treated with ICI therapy 3 . Indeed, vitiligo correlated with statistically significant differences in overall survival among patients with metastatic melanoma 3 . The present study investigated changes (Δ) in serum levels of CCL20 as well as CCL19, CCL21, CXCL5, and CXCL10 compared to baseline (day 0) in 57 patients with advanced melanoma treated using anti-PD1 antibodies.